Pharmacokinetics
Advancing discovery of how the body processes drugs
The mission of the University of Michigan Rogel Cancer Center's Pharmacokinetics Shared Resource is to facilitate both preclinical and clinical pharmacokinetic-based cancer research efforts through a range of services to help advance discovery:
- Discover new medicines
- Obtain research funding
- File patent applications
- Publish academic research findings
Pharmacokinetics Objectives
Our pharmacokinetics team studies molecular ADME (absorption, distribution, metabolism, and excretion) and pharmacokinetics of drugs with three objectives:
- To support preclinical pharmacokinetics, drug metabolism and LC-MS analysis for lead compound selection and dose optimization in anticancer drug discovery and development
- To support clinical pharmacokinetics (Non-GLP), LC-MS analysis and dose optimization for clinical trials of anticancer drugs
- To enhance joint grant applications, joint publications and joint patent applications with Rogel Cancer Center members in pharmacokinetic (PK) studies
Service Highlights
- Access to state-of-the-art instrumentation for bioanalysis and MS imaging operated by highly-trained technicians
- Support for drug metabolism and PK of 2600 compounds for drug discovery and development since inception
- Six patents and $15M in grant funding from joint grant applications with Rogel Cancer Center members
- Free consultation for Rogel Cancer Center members
If you have questions about pharmacokinetics services, please contact our team:
Director: Duxin Sun, PhD
Co-Director: Amit Pai, PharmD
Manager: Bo Wen, PhD
Location: NCRC, Bldg 520, 3400
Phone: 734-615-3470